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The effect of estradiol treatment of the human mammary carcinoma cell MCF-7 on the adenylyl cyclase system was examined. Treatment with 
10 nM estradiol for 72 h increased the basal level of CAMP, and isoproterenol-, PGE,- or calcitonin-stimulated CAMP production. Estradiol also 
increased the response to cholera toxin but did not alter the response to forskolin. No significant change in growth rate was observed uring the 
72 h of estradiol treatment. In MCF-7 cell membranes the responsiveness to isoproterenol, PGE,, or cholera toxin was also enhanced by estradiol 
treatment. The cholera toxin-catalyzed ADP-ribosylation of Gsa in MCF-7 cell membranes was significantly increased by 72 h of treatment with 
estradiol. Consistent with this observation, the level of Gscc immunoreactivity was increased in the estradiol-treated cell membranes. Gn the other 
hand, pertussis toxin did not change the responsiveness to isoproterenol, PGE, or calcitonin in either control or estradiol-treated cells. In addition, 
ADP-ribosylation with pertussis toxin also did not reveal any change in Gi. These results clearly indicate that Gs expression is under the control 
of estradiol, and that this effect may contribute to the increased sensitivity of hormone-stimulated adenylyl cyclase activities in MCF-7 cells. 
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1. INTRODUCTION 
Estrogen has been reported to have an ability to reg- 
ulate target tissue sensitivity to other extracellular sig- 
nals by altering the expression and/or function of recep- 
tors and guanine nucleotide binding proteins (G pro- 
teins). Estradiol treatment increases the number of CX- 
adrenergic receptors in rabbit myometrium [l], while it 
decreases that of luteinizing hormone receptors in the 
rabbit corpora lutea [2]. Expression of certain types of 
G proteins fluctuates in the rat anterior pituitary during 
the estrous cycle [3], and in the myometrium during 
gestation [4]. Moreover, estradiol has been shown to 
enhance pertussis toxin-catalyzed ADP-ribosylation of 
a-subunits of G proteins in rat striatal neurons [5]. 
Estrogens play an important role in the growth of 
both normal and malignant mammary epithelial cells 
[6,7]. CAMP is another growth modulator for them [8- 
lo]. CAMP levels are elevated in several breast carcino- 
mas [l 11. Not only CAMP levels but also /?-adrenergic 
receptor concentration increase in parallel with the 
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growth of mammary glands during pregnancy [12,13]. 
These observations uggest hat estrogens may act as a 
modulator of the signal transduction pathway, involv- 
ing CAMP as a second messenger, to stimulate cell 
growth. However, no precise role of estrogens on 
hormone-mediated CAMP production in mammary epi- 
thelia is known. So we asked whether estradiol modu- 
lates the signal transduction system in MCF-7, a 
hormone-sensitive human mammary carcinoma cell 
line. We found that, not only the basal level of CAMP 
but also CAMP production in response to isoproterenol, 
PGE, or calcitonin, was increased after estradiol treat- 
ment. In an attempt to better understand this effect of 
estradiol, we examined the possible modulation of G 
protein levels by estradiol in MCF-7 cells and found 
that estradiol induced a significant increase in Gs& pro- 
tein levels without any alteration in the Gia protein 
level. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
The human mammary carcinoma cell line, MCF-7, was maintained 
in RPM1 1640 (Flow Laboratories, McLean, VA) supplemented with 
10% FBS. For experiments involving estrogen induction, the cells were 
passaged for at least 1 week in Phenol red-free RPM1 1640 containing 
10% heat-inactivated FBS prior to use. 
2.2. Membrane preparation 
After a 72 h treatment with estradiol, plasma membranes were 
obtained according to the method previously described by Gerwins et 
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al. [14]. Purified membranes were suspended in 25 mM Tris-HCl (pH 
7.5) and stored in aliquots at -80°C until use. 
2.3. Determination of CAMP levels and adenylyl cyclase activity 
MCF-7 cells were plated at a density of 1 x lO?well into 24-well 
multidishes with 1 ml Phenol red-free RPM1 1640 containing 10% 
heat-inactivated FBS. After 48 h incubation, 10 nM estradiol or vehi- 
cle (0.001% ethanol) was added to culture medium to the desired 
concentration and the cells were further incubated for 12-72 h. To 
examine the response to isoproterenol, PGE,, calcitonin, cholera toxin 
or forskolin, the medium was replaced with FBS-free medium contain- 
ing 0.1% BSA and 2 mM IBMX, and test solution was added 30 min 
thereafter. At the end of a 10 min treatment, cellular CAMP was 
extracted by sonicating for 10 s in 0.1 N HCl. Adenylyl cyclase activity 
of the membrane was assayed as described previously [15]. CAMP was 
measured with a Yamasa RIA kit. 
2.4. ADP-ribosylation of the membrane with cholera toxin 
Cholera toxin (1 mg/lOO ~1) was preactivated for 15 min at 37°C 
by treatment with 20 mM DTT in 50 mM K,HPOdKH,PO, (pH 7.0). 
The incubation mixture (100~1) contained 1OOpg preactivated cholera 
toxin, 35 or 70 pg membrane protein, 200 mM K,HPO,/KH,PO, (pH 
7.4), 1 mM ATP, 10 mM thymidine, 5 mM MgCl,, 1 mM GTP, 20 
&i [‘*PINAD (Du Pont-NEN Research Products, MA) and 5 PM 
NAD. After 10 min incubation at 37°C the reaction was terminated 
by addition of 1 ml stop solution containing 10 mM Tris-HCl (pH 7.4) 
and 1 mM NAD. The membrane was collected by centrifugation at 
12,000 x g for 15 min and washed twice with the stop solution. The 
membrane pellets were resuspended in 20 ,~l Laemmli’s sample buffer 
and boiled for 10 min. Samples were subjected to SDS-PAGE accord- 
ing to the method of Laemmli, with 10% acrylamide gels [16]. After 
completion of electrophoresis, gels were dried and exposed to X-ray 
films. 
2.5. Immunoblotting of G proteins 
Membranes were solubilized in Laemmli’s sample buffer and the 
proteins were separated using SDS-PAGE as described above. After 
transfer of proteins to nitrocellulose sheets, immunoreaction was per- 
formed as described [17]. The antiserum RM/l (Du Pont-NEN Re- 
search Products, MA), which was generated against the C-terminus 
of Gsa, was used to detect the 45 kDa and 52 kDa forms of Gsa. 
Synthetic salmon calcitonin(l-32) (calcitonin) was kindly donated 
from Yamanouchi Pharmaceutical Co. (Tokyo, Japan). Statistic anal- 
yses were performed using Student’s t-test. 
3. RESULTS 
We first examined the effect of e&radio1 treatment of 
MCF-7 cells on the responsiveness to isoproterenol, 
PGE, or calcitonin. As indicated previously, MCF-7 
Fig. 1. Effect of estradiol on the dose-response curve for isoprotere- 
nol-, PGEZ- or calcitonin-stimulated CAMP production in MCF-7 
cells. Cells were preincubated without (0) or with 10 nM estradiol (0) 
for 72 h. After preincubation, cells were treated with the indicated 
concentrations of (A) isoproterenol, (B) PGE,, or (C) calcitonin, for 
10 min in the presence of 2 mM IBMX. Each point shows the 
mean f S.D. of triplicate determinations from one of two independent 
experiments. 
cells possess isoproterenol, PGE, and calcitonin recep- 
tors coupled to adenylyl cyclase [18]. Treatment of 10 
nM estradiol for 72 h resulted in an increase in the 
CAMP production stimulated by these agonists (Fig. 1). 
In addition, there is a significant increase of basal 
CAMP levels in MCF-7 cells treated with estradiol as 
compared with the control (12.1 f 1 .l pmol/well vs. 
7.8 f 0.5 pmol/well; P < 0.01). Timeecourse studies of 
the effects of estradiol on calcitonin and PGE, re- 
sponses revealed that they required at least 48 h of 
Table I 
Effect of estradiol on cholera toxin- or forskolin-stimulated CAMP production in MCF-7 cells 
Cholera toxin @g/ml) Forskolin (nM) 
0 0.1 1 0 10 100 
Control 8.6 f 0.9 78 f 6 423 f 28 7.9 + 0.4 59 f 1 318 f 22 
Estradiol 12.7 f 0.4* 98 f 7* 561 f 12* 11.3 f 1.1* 61 f6 29Of12 
Cells were preincubated with or without 10 nM estradiol for 72 h. After preincubation, cells were treated with the indicatedconcentrations of cholera 
toxin for 60 min, or forskolin for 10 min, in the presence of 2 mM IBMX. CAMP production is expressed as pmol/well. Each value represents the 
mean f S.D. of triplicate determinations. *P < 0.01 compared to the control value. 
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Fig. 2. Time dependence of estradiol effect on isoproterenol-, PGE,-, 
or calcitonin-stimulated CAMP production in MCF-7 cells. Cells were 
preincubated without (0) or with 10 nM estradiol (0) for up to 72 h. 
After preincubation, cells were treated with (A) 1 PM isoproterenol, 
(B) 1 PM PGEr, or (C) 10 nM calcitonin for 10 min in the presence 
of 2 mM IBMX. Each point shows the mean f SD. of triplicate 
determinations from one of two independent experiments. 
estradiol treatment o be evident, while the isoprotere- 
no1 response was significantly increased after 12 h treat- 
ment with estradiol (Fig. 2). No significant change in 
growth rate was observed during the 72 h of estradiol 
treatment (data not shown). 
Estradiol treatment of MCF-7 cells also increased 
cholera toxin-stimulated CAMP production, but did not 
alter forskolin-stimulated CAMP production (Table I). 
These estradiol effects on the adenylyl cyclase system 
were also examined using MCF-7 cell membrane prepa- 
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Fig. 3. Quantitation of G proteins in membranes from MCF-7 cells, 
using ADP-ribosylation and immunoblotting. Membranes were pre- 
pared from control cells and cells treated with 10 nM estradiol (E,) 
for 72 h. (A) ADP-ribosylation of G proteins with cholera toxin. (B) 
Immunoblotting of the Gscz subunit. Lanes 1 and 2 were loaded with 
35 ,ug of membrane protein, and lanes 3 and 4 with 70,ug of membrane 
protein. 
rations (Table II). Although calcitonin-stimulated 
CAMP production in the cell membrane was too small 
to be detected, the responsiveness to isoproterenol, 
PGE2 or cholera toxin was further enhanced by a 72 h 
treatment of estradiol. 
In order to investigate whether the observed changes 
in responsiveness to these agonists were due to quantita- 
tive or qualitative changes in G proteins, we performed 
ADP-ribosylation with cholera toxin and immunoblot- 
ting with an antibody against the Gscl subunit. Cholera 
toxin induced the ADP-ribosylation of the 45kDa and 
52-kDa forms of Gsa on SDS-polyacrylamide gels (Fig. 
3). The cholera toxin-catalyzed ADP-ribosylation of 
Gsa of an MCF-7 cell membrane fraction was signifi- 
cantly increased by a 72 h treatment of estradiol, sug- 
gesting an increased amount of Gsa. This was con- 
firmed by measuring the level of Gsa by the im- 
munoblotting method. 
Pretreatment of cells with pertussis toxin did not alter 
the responsiveness of cells to isoproterenol, PGE, or 
calcitonin in either control or estradiol-treated cells 
(data not shown). In addition, ADP-ribosylation with 
pertussis toxin also did not reveal any change in the 
level of Gi after 72 h of treatment of estradiol (data not 
shown). 
Table II 
Effect of estradiol on isoproterenol-, PGE,-, or cholera toxin-stimulated CAMP production in MCF-7 cell membranes 
None Isoproterenol 
(0.1 mM) 
PGE2 
(0.1 mM) 
Cholera toxin 
(20 &ml) 
Control 2.99 + 0.15 3.78 ?r 0.14 5.02 f 0.25 4.11 f 0.13 
Estradiol 2.68 k 0.21 4.54 * 0.43* 5.89 f 0.16* 4.65 f 0.25* 
Membranes were prepared from control cells and cells treated with 10 nM estradiol for 72 h. Membranes were treated with the indicated 
concentrations of isoproterenol, PGE, or cholera toxin, for 30 min in the presence of 2 mM IBMX. Cholera toxin was preactivated as described 
in section 2. CAMP production is expressed as pmol/30 min/pg protein. Each value represents the mean + S.D. of triplicate determinations. *P c 0.01 
compared to the control value. 
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4. DISCUSSION 
In the present study, we have demonstrated the en- 
hancement of hormone-stimulated adenylyl cyclase ac- 
tivities by estradiol in MCF-7, a human mammary car- 
cinoma cell line. Associated with this were increases in 
the specific cholera toxin substrates and in Gsol im- 
munoreactivity. These results suggest hat estradiol ex- 
erts its stimulating influence on adenylyl cyclase-acti- 
vating pathway through increasing Gsa expression. On 
the other hand, inhibitory G protein (Gi) seemed un- 
likely to be affected by 72 h treatment with estradiol. 
There are few reports that describe the regulatory role 
of estrogens on Gs protein function and/or expression 
[2-4,19]. Treatment of rats with estradiol induced a sig- 
nificant reduction in immunoreactivity towards most of 
the pituitary G proteins except Gial, which remained 
unchanged, and Gsc142, which increased [3]. Estradiol 
caused reduction of Gs function in rat luteal cells using 
reconstitution assay that employs a cyc- variant of the 
S49 mouse lymphoma cell line [2]. In rabbit myomet- 
rium, while estradiol reduced cholera toxin-catalyzed 
ADP-ribosylation, the hormone did not alter Gs activ- 
ity stimulated by GTP, GPP or NaF [19]. These obser- 
vations have not made it clear whether estrogen-in- 
duced modification of G protein function was actually 
accompanied by altered levels of G proteins. There are 
several findings that differences in the extent of ADP- 
ribosylation reflect those in properties of G proteins 
rather than their total amounts [20,21]. For example, 
Maus [S] reported that pretreatment of striatal neurons 
from mouse embryos in primary culture with estradiol 
enhanced functions of Gi and Go by stabilizing associ- 
ation between heterotrimeric subunits with no change 
in their total amount. In the present study, we found 
that estradiol induced similar increases in 45 kDa and 
52 kDa Gsa by means of an ADP-ribosylation proce- 
dure, along with an increase in the hormone-stimulated 
adenylyl cyclase activities. Similar increases were also 
observed in both forms of Gsa by immunoblotting. 
Therefore, to our knowledge, this is the first report 
demonstrating that estradiol increased Gscl expression, 
which resulted in the increased sensitivity of hormone- 
stimulated adenylyl cyclase activity in MCF-7 cells. 
Time-courses of the effects of estradiol on calcitonin 
and PGE, responses were similar, requiring at least 48 
h of estradiol treatment to be evident, while the iso- 
proterenol response was significantly increased at 12 h 
of exposure. Although there has been no report that 
describes the timecourse of estrogen-induced altera- 
tion in G protein expression, an early effect of estradiol 
on isoproterenol-stimulated CAMP production seems 
unlikely to be mediated by alteration in the Gscr. level. 
Rather, involvement of alteration in/?-adrenergic recep- 
tor number should be considered, because there are 
some indications that B-adrenergic receptor number 
fluctuates within a short time range: (i) increase in /I- 
28 
adrenergic receptor number induced by treatment of 
osteosarcoma ROS 17/2.8 cells with dexamethasone 
was observed at 12 h [22], although there have been no 
such findings with estrogen; (ii) increase in /I-adrenergic 
receptor number in rat mammary gland correlated with 
parallel increases in plasma estradiol and progesterone 
levels during pregnancy [12]. It was reported that Gsol 
interacts with ion channels [23] in addition to adenylyl 
cyclase. This observation suggests that estradiol might 
modify other transduction pathways. Further charac- 
terization of estradiol regulation of signal transduction 
pathways could provide insight into other such systems. 
The finding that Gsa expression is up-regulated by 
estradiol in estrogen receptor-positive mammary carci- 
noma cells is interesting when considering the effect of 
estrogen on their growth. Estradiol is a potent growth 
promoter and its effects are, in part, mediated by up- 
regulation of EGFITGF-a receptor number [24] and 
secretion of growth factors such as TGF-a [25] and 
IGF-I [26]. However, in serum-free medium, it showed 
no growth effect on cells from normal, benign, and 
malignant human mammary cells in primary culture 
[26], and estradiol was capable of enhancing the growth- 
stimulating effect of EGF in the same primary culture 
of human mammary carcinoma. Moreover, in the pres- 
ence of serum, estradiol could stimulate growth of cells 
from normal and malignant mammary tissues [27]. 
These observations uggest hat estrogen might act as 
a modulator of cellular signal transduction pathways of 
growth factors, rather than acting directly as a mitogen. 
CAMP also modulates the growth of breast epithelial 
cells. Although it is not clear whether CAMP alone stim- 
ulates or inhibits their growth, possible involvement of 
the nucleotide in cell growth is suggested from the find- 
ing that growth factors (EGF, FGF, or MSA) and chol- 
era toxin have shown a synergistic effect on growth of 
cells from normal mouse mammary glands and some 
kinds of mouse mammary tumors [28]. CAMP levels 
increased in parallel with mammary gland growth dur- 
ing pregnancy [13], and they were elevated in several 
mammary carcinomas [111. In addition to up-regulation 
of EGFITGF-tx receptor number and their secretion, 
these findings suggest hat estrogens might be involved 
in the growth of normal and malignant mammary tis- 
sues by enhancing Gs function and/or expression. 
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